Accurate Diagnosis for Brain Diseases
- Brain diseases are difficult to diagnose
- Brain Scans: 36 million per year (US)
- Spinal Taps: 363,000 per year (US)
- Treatable brain diseases like Multiple Sclerosis (MS) and Parkinson’s Disease (PD) are misdiagnosed 18 to 30% of the time
- 2 million Americans suffer from MS or PD
The Challenge
Invasive and Inaccurate
Screening protocols for neurologic diseases – including Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), Parkinson’s Disease (PD), and Alzheimer’s Disease (AD) – currently rely on imprecise and invasive diagnostic procedures.
Some of these brain disease are misdiagnosed up to a third of the time, leading to incorrect treatment protocols and the use of wrong medications.
Our Solution
RNA Biomarkers
FBB Biomed’s newly discovered RNA biomarkers increase diagnostic accuracy at the time of screening by providing a molecular diagnostic for MS, PD, and AD.
FBB Biomed’s pre-clinical research has demonstrated significant potential for earlier, more accurate diagnosis of these diseases.
Our Product
NGS-based Blood Test
FBB Biomed’s proprietary reagent and bioinformatics software power our blood test based on RNA biomarkers. Our test provides neurologists with a liquid biopsy for the diagnosis of Multiple Sclerosis, Parkinson’s Disease, and Alzheimer’s Disease.
Our test runs on standard laboratory sequencing equipment and protocols. No new hardware or processes required.
Actionable Clinical Utility
Use Cases
Early Diagnosis
Is this patient suffering from neurodegeneration?
Differential Diagnosis
Which neurologic disease does this patient have?
Patient Monitoring
How effective has the prescribed therapy been so far?
From the Scientific Community
What Others Say About Us
“If we could look at biomarkers and understand who is going to progress to the most severe form of the disease, it also could change the therapies that we would offer to that patient. This is where we could have a tremendous impact on the whole course of a disease.”
Dr. Patricia Winokur, Executive DeanCarver College of Medicine, University of Iowa 
“If we could identify biomarkers that are associated with a poor prognosis for COVID-19 or any other disease, then we would know – prior to that person having a poor outcome – that they were at risk for a poor outcome.”
Dr. Richard Smith, DirectorIowa Institute of Human Genetics, University of Iowa 
“We take all the data and let the machine learning approach guide us through which genes or which transcripts or which patterns are actually important rather than putting our own bias into what we think is important.”
Dr. Henry Keen, Research ScientistIowa Institute of Human Genetics, University of Iowa 
“FBB Biomed’s research does not look into single values of the immune status but looks at the history of the immune system and gives a complete picture of what has happened to that individual person.”
Dr. Heinz Hänel, Advisor to FBB BiomedHonorary Professor, Goethe University 